Age-Related Macular Degeneration Clinical Trials

Recruiting Age-Related Macular Degeneration studies

• A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
  NCT07144137Complement TherapeuticsGeographic Atrophy Secondary to Age-related Macular DegenerationMountain View, California
• Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
  NCT04339764PHASE1, PHASE2National Eye Institute (NEI)Dry Age-Related Macular DegenerationBaltimore, Maryland
• An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
  NCT07392255PHASE1, PHASE2Complement TherapeuticsGeographic Atrophy Secondary to Age-related Macular DegenerationCarmel, Indiana
• Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
  NCT07007065PHASE3AbbVieNeovascular Age-related Macular DegenerationMesa, Arizona
• National Eye Institute Biorepository for Retinal Diseases
  NCT01496625National Eye Institute (NEI)Age-Related Macular DegenerationBethesda, Maryland
• A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
  NCT07440225PHASE2, PHASE3EyeBiotech Ltd.Macular DegenerationScottsdale, Arizona
• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
  NCT04853251PHASE4Genentech, Inc.Neovascular Age-related Macular DegenerationMesa, Arizona
• A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
  NCT07614776PHASE3AmgenNeovascular Age-related Macular DegenerationFullerton, California
• Extension Study for the Port Delivery System With Ranibizumab (Portal)
  NCT03683251PHASE3Hoffmann-La RocheNeovascular Age-Related Macular DegenerationPhoenix, Arizona
• Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
  NCT07482176PHASE3Adverum Biotechnologies, Inc.Neovascular Age-Related Macular Degeneration (nAMD)Mesa, Arizona
• A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
  NCT06557460PHASE2Regenerative Patch Technologies, LLCDry Age-related Macular DegenerationHuntington Beach, California
• A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
  NCT06351605LumiThera, Inc.Dry Age-related Macular DegenerationBeverly Hills, California

See all 54 recruiting trials →

Age-Related Macular Degeneration trials by state

• California
• Texas
• New York
• Florida
• Pennsylvania
• Massachusetts
• Ohio
• Illinois
• North Carolina
• Maryland
• Georgia
• Tennessee

Age-Related Macular Degeneration trials by metro

• New York
• Houston
• Boston
• Chicago
• Philadelphia
• Los Angeles
• Dallas
• Atlanta
• Miami
• Nashville
• Rochester
• Baltimore

Frequently asked questions

How do I find recruiting Age-Related Macular Degeneration clinical trials?

Browse the actively recruiting Age-Related Macular Degeneration studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.

Are Age-Related Macular Degeneration clinical trials free to join?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

Who can take part in a Age-Related Macular Degeneration clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.